Literature DB >> 1601995

Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine.

C P Sparrow1, T W Doebber, J Olszewski, M S Wu, J Ventre, K A Stevens, Y S Chao.   

Abstract

The oxidative modification of low density lipoprotein (LDL) may play an important role in atherosclerosis. We found that the antioxidant N,N'-diphenyl-1,4-phenylenediamine (DPPD) inhibits in vitro LDL oxidation at concentrations much lower than other reported antioxidants. To test whether DPPD could prevent atherosclerosis, New Zealand White rabbits were fed either a diet containing 0.5% cholesterol and 10% corn oil (control group) or the same diet also containing 1% DPPD (DPPD-fed group) for 10 wk. Plasma total cholesterol levels were not different between the two groups, but DPPD feeding increased the levels of triglyceride (73%, P = 0.007) and HDL cholesterol (26%, P = 0.045). Lipoproteins from DPPD-fed rabbits contained DPPD and were much more resistant to oxidation than control lipoproteins. After 10 wk, the DPPD-fed animals had less severe atherosclerosis than did the control animals: thoracic aorta lesion area was decreased by 71% (P = 0.0007), and aortic cholesterol content was decreased by 51% (P = 0.007). Although DPPD cannot be given to humans because it is a mutagen, our results indicate that orally active antioxidants can have antiatherosclerotic activity. This strongly supports the theory that oxidized LDL plays an important role in the pathogenesis of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1601995      PMCID: PMC295887          DOI: 10.1172/JCI115793

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Determination of cholesterol using o-phthalaldehyde.

Authors:  L L Rudel; M D Morris
Journal:  J Lipid Res       Date:  1973-05       Impact factor: 5.922

2.  Calcium antagonists as anti-atherosclerotic agents.

Authors:  P D Henry
Journal:  Arteriosclerosis       Date:  1990 Nov-Dec

Review 3.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

4.  Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis.

Authors:  M T Quinn; S Parthasarathy; L G Fong; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  Enzymatic modification of low density lipoprotein by purified lipoxygenase plus phospholipase A2 mimics cell-mediated oxidative modification.

Authors:  C P Sparrow; S Parthasarathy; D Steinberg
Journal:  J Lipid Res       Date:  1988-06       Impact factor: 5.922

6.  Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins.

Authors:  T B Rajavashisth; A Andalibi; M C Territo; J A Berliner; M Navab; A M Fogelman; A J Lusis
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

7.  Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition.

Authors:  R McPherson; M Hogue; R W Milne; A R Tall; Y L Marcel
Journal:  Arterioscler Thromb       Date:  1991 May-Jun

8.  Inhibition of IL-1 beta expression in THP-1 cells by probucol and tocopherol.

Authors:  A L Akeson; C W Woods; L B Mosher; C E Thomas; R L Jackson
Journal:  Atherosclerosis       Date:  1991-02       Impact factor: 5.162

9.  Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer.

Authors:  G Franceschini; M Sirtori; V Vaccarino; G Gianfranceschi; L Rezzonico; G Chiesa; C R Sirtori
Journal:  Arteriosclerosis       Date:  1989 Jul-Aug

10.  Cholesteryl ester synthesis in macrophages: stimulation by beta-very low density lipoproteins from cholesterol-fed animals of several species.

Authors:  R W Mahley; T L Innerarity; M S Brown; Y K Ho; J L Goldstein
Journal:  J Lipid Res       Date:  1980-11       Impact factor: 5.922

View more
  28 in total

Review 1.  Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants.

Authors:  Yan-Jun Xu; Paramjit S Tappia; Nirankar S Neki; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

2.  Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole.

Authors:  L Iuliano; A R Colavita; C Camastra; V Bello; C Quintarelli; M Alessandroni; F Piovella; F Violi
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

Review 3.  The response-to-retention hypothesis of early atherogenesis.

Authors:  K J Williams; I Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

4.  Antioxidant: a new role for RU-486 and related compounds.

Authors:  S Parthasarathy; A J Morales; A A Murphy
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

5.  Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells.

Authors:  J M Heery; M Kozak; D M Stafforini; D A Jones; G A Zimmerman; T M McIntyre; S M Prescott
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 6.  Clinical trials of vitamin E in coronary artery disease: is it time to reconsider the low-density lipoprotein oxidation hypothesis?

Authors:  Jay W Heinecke
Journal:  Curr Atheroscler Rep       Date:  2003-03       Impact factor: 5.113

Review 7.  Why are low-density lipoproteins atherogenic?

Authors:  S G Young; S Parthasarathy
Journal:  West J Med       Date:  1994-02

8.  Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions.

Authors:  A Daugherty; J L Dunn; D L Rateri; J W Heinecke
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

9.  A comparison of the antiatherogenic effects of probucol and of a structural analogue of probucol in low density lipoprotein receptor-deficient rabbits.

Authors:  J Fruebis; D Steinberg; H A Dresel; T E Carew
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

10.  Effects of ACE inhibitors on oxidation of human low density lipoprotein.

Authors:  E G Godfrey; J Stewart; H J Dargie; J L Reid; M Dominiczak; C A Hamilton; J McMurray
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.